Form 4: MannKind Director Exercises Options and Sells Shares Under 10b5-1 Plan

Steven B. Binder, a director at MannKind Corp, exercised stock options and sold shares on November 22, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On November 22, 2024, Steven B. Binder, a director at MannKind Corp, exercised options to acquire 67,536 shares of common stock at a price of $1.47 per share.
• Simultaneously, Mr. Binder sold 67,536 shares of common stock at a weighted average price of $6.89 per share, with prices ranging from $6.83 to $6.96.
• These transactions were executed under a Rule 10b5-1 trading plan established on August 16, 2024.
• Following these transactions, Mr. Binder directly owns 1,075,026 shares of MannKind common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative in itself.

Risks

• The sale of shares by a director could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing related to insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives and directors of publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
• Similar filings are regularly made by insiders at companies like Eli Lilly, Novo Nordisk, and Sanofi, which are also in the pharmaceutical and biotechnology sectors.

Stakeholder Impact

• The sale of shares by a director could cause a minor negative reaction from shareholders.

Key Dates

Keywords

MannKind, Director, Stock Options, Share Sale, Form 4, 10b5-1 Plan, Insider Trading